# Proteome Sciences plc 46% Revenue growth, 57% increase in sales

- Link: https://www.directorstalkinterviews.com/proteome-sciences-plc-46-revenue-growth-57-increase-sales/412726218
- Published: 2017-03-28T07:23:13+01:00
- Author: Giles Arbor

**Proteome Sciences plc** (LON:PRM) has today announced its audited results for 
the year ended 31 December 2016.

Highlights:

· 46% revenue growth to £2.74m, underpinned by 57% increase in sales of TMT® reagents
to £1.39m; costs and margins as expected

· Appointment of new Chief Executive Officer in June; creation of Chief Compliance
Officer role to oversee Good Clinical Laboratory Practice (GCLP) accreditation

· £3.3m fundraise in October, adding a number of new institutional investors, and
a revised strategy based on biomarker services, TMT® reagent synthesis and bioinformatics

· Conversion to a higher value project portfolio, with completion of 25% fewer service
contracts generating 57% greater revenues than in 2015

· Validation and optimisation of a new class of antibodies against our patented 
stroke biomarker proteins by our partner, Randox Laboratories, with assay launches
expected in 2017

· Initiation of third party due diligence on our casein kinase 1 delta (CK1D) inhibitor
portfolio

> **Jeremy Haigh, Chief Executive of Proteome Sciences Plc, commented:** “While 
> we are satisfied with solid progress during 2016, there is clearly much yet to
> do if we want to realise the full commercial value of our proteomic technologies.
> The Company is in a transition phase as we seek to expand our customer base to
> secure larger and more durable contracts for our services. The recent decision
> to consolidate our laboratory facilities in Frankfurt was difficult given our 
> UK heritage but we firmly believe it to be in the best interests of the Company
> and our shareholders. We look forward to healthy progress during 2017, to the 
> imminent arrival of our new Chief Commercial Officer, and to providing further
> updates through the course of the year.”

Share on:
